Gradishar, William J.

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 604

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 439

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial

Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W. J., Masuda, N., et al. (2019) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 99

SOPHIA primary analysis: a phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)

Rugo, H. S., Im, S.-A., Wright, G. L. S., Escriva-de-Romani, S., DeLaurentiis, M., Cortes, J., Bahadur, S. W., Haley, B. B., Oyola, R. H., Riseberg, D. A., et al. (2019) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 80

Barriers to the Use of Personalized Medicine in Breast Cancer

Weldon, C. B., Trosman, J. R., Gradishar, W. J., Benson, A. B., & Schink, J. C. (2012) · Journal of Oncology Practice

BRCA gene mutations in cancerBreast Cancer Treatment Studies

Cited by 76

Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results From the FoRtitude Randomized Trial

Wagner, L. I., Tooze, J. A., Hall, D. L., Levine, B. J., Beaumont, J., Duffecy, J., Victorson, D., Gradishar, W., Leach, J., Saphner, T., et al. (2021) · JNCI: Journal of the National Cancer Institute

Cancer survivorship and careDigital Mental Health Interventions

Cited by 67

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma: An Illinois cancer center study

Gradishar, W. J., Vogelzang, N. J., Kilton, L. J., Leibach, S. J., Rademaker, A. W., French, S., & Benson, A. B. (1995) · Investigational New Drugs

Sarcoma Diagnosis and TreatmentCancer therapeutics and mechanisms

Cited by 49

Study design and protocol for tailored Acceptance and Commitment Therapy (ACT) to optimize quality of life in women living with metastatic breast cancer

Moreno, P. I., Horner, F. S., Torzewski, J. B., Thomas, J. L., Gradishar, W., Victorson, D., & Penedo, F. J. (2022) · Contemporary Clinical Trials Communications

Mindfulness and Compassion InterventionsCancer survivorship and care

Cited by 12

Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients

Liao, N., Li, C., Gradishar, W. J., Klimberg, V. S., Roshal, J. A., Yuan, T., Agarwala, S. S., Valero, V. K., Swain, S. M., Margenthaler, J. A., et al. (2025) · JCO Clinical Cancer Informatics

Artificial Intelligence in Healthcare and EducationAI in cancer detection

Cited by 7